Figure 1.
Altered NK-cell homeostasis in a subset of patients with neutropenia. (A) Study design. (B-C) Flow cytometry analysis of frequencies of CD56bright/dim among total NK cells. A subset of 14 patients with neutropenia (NP) with elevated levels of CD56bright cells (defined as >HD mean +3 standard deviations, were relabeled NKimm. (D) Frequencies of CD56bright cells in NKimm patients sampled 2 years apart. (E) Frequency of total CD56+ NK among PBMCs. (F) Cell counts of CD56+ NK cells. (G-H) Subset level phenotyping of CD56dim NK cells based on NKG2A, KIR, and CD57 expression. (I) The frequency of CMV+ donors with an adaptive NK-cell population (aNK) within each group. HD (n = 20), NP (n = 39), and NKimm (n = 14). *P < .05; **P < .01; ***P <.001; ****P < .001 by nonparametric test, and binomial distribution (I).

Altered NK-cell homeostasis in a subset of patients with neutropenia. (A) Study design. (B-C) Flow cytometry analysis of frequencies of CD56bright/dim among total NK cells. A subset of 14 patients with neutropenia (NP) with elevated levels of CD56bright cells (defined as >HD mean +3 standard deviations, were relabeled NKimm. (D) Frequencies of CD56bright cells in NKimm patients sampled 2 years apart. (E) Frequency of total CD56+ NK among PBMCs. (F) Cell counts of CD56+ NK cells. (G-H) Subset level phenotyping of CD56dim NK cells based on NKG2A, KIR, and CD57 expression. (I) The frequency of CMV+ donors with an adaptive NK-cell population (aNK) within each group. HD (n = 20), NP (n = 39), and NKimm (n = 14). *P < .05; **P < .01; ***P <.001; ****P < .001 by nonparametric test, and binomial distribution (I).

Close Modal

or Create an Account

Close Modal
Close Modal